Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.53 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713038 | 0.89 | TP53 (0.48) | LMNAMAPTMEN1RAB9AKMT2A | |
| SCHEMBL5739759 | 0.85 | MEN1 (0.52) | ALDH1A1KCNK3MAPTMEN1RAB9A | |
| SCHEMBL4715305 | 0.84 | F2 (0.54) | LMNAMAPTCCNA2CDK2CCNA1 | |
| SCHEMBL5739653 | 0.83 | NPC1 (0.56) | ALDH1A1GAAMAPTCCNA2CDK2 | |
| SCHEMBL4710882 | 0.81 | SMN1; SMN2 (0.73) | LMNAALDH1A1KCNK3MAPTCCNA2 | |
| SCHEMBL4713719 | 0.79 | KDM4E (0.49) | ALDH1A1GAAKCNK3ADCY1MAPT | |
| SCHEMBL5738935 | 0.78 | ADORA3 (0.61) | LMNAMAPTCCNA2CDK2CCNA1 | |
| SCHEMBL4712235 | 0.78 | LMNA (0.46) | LMNAGAAKCNK3KCNK9RXFP1 | |
| SCHEMBL5738513 | 0.78 | CCNA2 (0.47) | LMNAMAPTCCNA2CDK2CCNA1 | |
| SCHEMBL4714403 | 0.77 | F2 (0.51) | LMNAALDH1A1GAAKCNK3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644371-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMA INC (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| CN-1802373-A | Pyrazoloisoquinoline derivatives as kinase inhibitors | AVENTIS PHARMA INC (US) | 2006-07-12 | — | — | CN | disclosed |
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | LMNA 1662/4885ALDH1A1 3249/4885GAA 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.